172348-58-2 Usage
Uses
Used in Drug Development:
L-Proline, 3-cyclohexyl-N-[(1,1-dimethylethoxy)carbonyl]-N-[2-(1,1-dimethylethoxy)-2-oxoethyl]-D-alanylis used as a building block for the synthesis of new compounds with potential therapeutic properties. Its unique structure allows for specific interactions with biological systems, making it a promising candidate for the development of novel drugs.
Used in Biochemistry:
In the field of biochemistry, L-Proline, 3-cyclohexyl-N-[(1,1-dimethylethoxy)carbonyl]-N-[2-(1,1-dimethylethoxy)-2-oxoethyl]-D-alanylcan be utilized for studying the interactions between amino acids and other biomolecules. Its presence in various chemical reactions can provide insights into the mechanisms of protein folding, enzyme catalysis, and other biological processes.
Used in Medicinal Chemistry:
L-Proline, 3-cyclohexyl-N-[(1,1-dimethylethoxy)carbonyl]-N-[2-(1,1-dimethylethoxy)-2-oxoethyl]-D-alanylis used as a versatile chemical in medicinal chemistry for the design and synthesis of new pharmaceutical agents. Its unique functional groups and cyclohexyl group can be exploited to create compounds with specific biological activities, potentially leading to the discovery of new treatments for various diseases.
Check Digit Verification of cas no
The CAS Registry Mumber 172348-58-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,7,2,3,4 and 8 respectively; the second part has 2 digits, 5 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 172348-58:
(8*1)+(7*7)+(6*2)+(5*3)+(4*4)+(3*8)+(2*5)+(1*8)=142
142 % 10 = 2
So 172348-58-2 is a valid CAS Registry Number.
172348-58-2Relevant academic research and scientific papers
Unique overlap in the prerequisites for thrombin inhibition and oral bioavailability resulting in potent oral antithrombotics
Adang, Anton E. P.,De Man, Adrianus P. A.,Vogel, Gerard M. T.,Grootenhuis, Peter D. J.,Smit, Martin J.,Peters, Co A. M.,Visser, Arie,Rewinkel, Jos B. M.,Van Dinther, Theo,Lucas, Hans,Kelder, Jan,Van Aelst, Sjoerd,Meuleman, Dick G.,Van Boeckel, Constant A. A.
, p. 4419 - 4432 (2007/10/03)
Despite intense research over the last 10 years, aided by the availability of X-ray structures of enzyme-inhibitor complexes, only very few truly orally active thrombin inhibitors have been found. We conducted a comprehensive study starting with peptide transition state analogues (TSA). Both hydrophobic nonpeptide analogues as well as hydrophilic peptidic analogues were synthesized. The bioavailability in rats and dogs could be drastically altered depending on the overall charge distribution in the molecule. Compound 27, a tripeptide TSA inhibitor of thrombin, showed an oral bioavailability of 32% in rats and 71% in dogs, elimination half-lives being 58 and 108 min, respectively. The thrombin inhibition constant of compound 27 was 1.1 nM, and in an in vivo arterial flow model, the ED50 was 5.4 nmol/kg.min, comparable to known non-TSA inhibitors. A molecular design was found that combines antithrombotic efficiency with oral bioavailability at low dosages.
